Results 51 to 60 of about 30,573 (214)
Antithrombin: Deficiency, Diversity, and the Future of Diagnostics
Mass Spectrometry Reviews, EarlyView.ABSTRACT Our healthcare system provides reactive sick‐care, treating patients after symptoms have appeared by prescription of generic and often suboptimal therapy. This strategy brings along high costs and high pressure which is not sustainable.
Mirjam Kruijt +2 more
wiley +1 more source
The eukaryotic initiation factor 2 kinase GCN2 protects against hepatotoxicity during asparaginase treatment [PDF]
, 2013 Asparaginase is an important drug in the treatment regimen for acute lymphoblastic leukemia. Asparaginase depletes circulating asparagine and glutamine, activating an amino acid stress response (AAR) involving phosphorylation of eukaryotic initiation ...
Anthony, Tracy G. +4 more
core +1 more source
Medicinal Research Reviews, EarlyView.ABSTRACT CRISPR‐Cas9 genome‐wide screening has been instrumental towards identifying novel targets for drug discovery in cancer research. However, much of this research has centred specifically on adult cancers, with paediatric cancers being underserviced by current research and screening.
Steven He +2 more
wiley +1 more source
A Study on L-Asparaginase of Nocardia levis MK-VL_113
The Scientific World Journal, 2012 An enzyme-based drug, L-asparaginase, was produced by Nocardia levis MK-VL_113 isolated from laterite soils of Guntur region. Cultural parameters affecting the production of L-asparaginase by the strain were optimized.
Alapati Kavitha, Muvva Vijayalakshmi
doaj +1 more source
Frontiers in Oncology, 2023 Pegylated (PEG)-asparaginase is an established treatment for acute lymphoblastic leukemias that exhibits an antitumor effect by depleting asparagine, an amino acid essential for leukemia cell protein synthesis. Pancreatitis with hypertriglyceridemia is a
Todd William Mudd +3 more
doaj +1 more source
Imaging of Abdominal Complications in Children With Acute Lymphoblastic Leukaemia
Journal of Medical Imaging and Radiation Oncology, EarlyView.ABSTRACT Acute lymphoblastic leukaemia (ALL) is the most common paediatric malignancy and remains one of the most common causes of cancer‐related death in children and adolescents. Five‐year overall survival rates now exceed 90% with current multidrug chemotherapeutic regimens. This improvement, coupled with the toxicity of chemotherapy, has led to the
Luke R. Holmes +2 more
wiley +1 more source
Production of extracellular L- asparaginase by halophilic bacterium vibrio sp.
Biological Journal of Microorganism, 2016 Introduction: L-Asparaginase is an anti-neoplastic drug used in lymphoblastic leukemia chemotherapy. Nowadays, this enzyme derived from bacterial sources, mostly L-asparaginase II from Escherichia coli and in lesser amount L-asparaginase of Erwinia sp ...
Mahdis Zolfaghar +2 more
doaj
Health Economics Review, 2019 Background L-asparaginase is a key component of treatment for patients with acute lymphoblastic leukaemia (ALL) in the UK. Commonly used forms of asparaginase are native E.
Xingdi Hu +5 more
doaj +1 more source
Jurnal Pascapanen dan Bioteknologi Kelautan dan Perikanan, 2019 L-asparaginase (EC 3.5.1.1) adalah enzim yang menghidrolisis asam amino L-asparagin menjadi amonia dan asam aspartat. Enzim ini mempunyai manfaat utama dalam bidang farmasi dan industri pangan.
Asep Awaludin Prihanto +2 more
doaj +1 more source
Reply: Methotrexate neurotoxicity due to drug interactions: an inadequate folinic acid effect [PDF]
, 2017 No abstract ...
Baird, Susan F. +5 more
core +1 more source